Glucotrack, INC 8-K filings

Glucotrack, Inc. has amended its Common Stock Purchase Agreement with White Lion Capital, LLC, adjusting terms related to commitment shares and potential future payments.

Glucotrack, Inc. announced definitive agreements for approximately $5.5 million in financing, comprising a $2.0 million equity round and a $3.5 million convertible debt follow-on investment.

Glucotrack's subsidiary, Lkahi Therapeutics, is moving forward with a simplified administration strategy for its LT-100 drug, aiming for a single injection instead of up to 15.

Glucotrack, Inc. files an amendment to its 8-K report to update details on an Exchange Agreement and a newly partitioned promissory note.

Glucotrack, Inc. has entered into an Exchange Agreement to partition a promissory note and allow for its conversion into company stock.

Glucotrack, Inc. has completed a strategic business combination with Lokahi Therapeutics, Inc., establishing a new public platform focused on healthcare asset development.

Glucotrack, Inc. has received notice of potential delisting from Nasdaq due to failure to meet minimum bid price and stockholders' equity requirements.

Glucotrack, Inc. reported Q1 2026 financial results and the submission of its Investigational Device Exemption (IDE) to the FDA for its implantable CBGM technology.

Glucotrack, Inc. has submitted an Investigational Device Exemption (IDE) application to the FDA for a U.S. clinical study of its novel implantable continuous blood glucose monitoring technology.

Glucotrack, Inc. has entered into an agreement to exchange a $988,000 promissory note for 1,300,000 shares of common stock.

Glucotrack, Inc. has entered into an Exchange Agreement to convert a portion of its outstanding promissory note into company stock, impacting its capital structure.

Glucotrack, Inc. announced its full year 2025 financial and operating results, highlighting progress in its implantable continuous blood glucose monitoring technology and a strengthened balance sheet.

Glucotrack, Inc. announced plans to submit an Investigational Device Exemption to the FDA in Q2 2026 for its novel continuous blood glucose monitoring technology, following successful international clinical trials.

Glucotrack, Inc. stockholders approved proposals for significant stock issuances to Sixth Borough Capital Fund and warrant holders, and ratified its independent auditor at a special meeting.

Glucotrack, Inc. announced the U.S. Patent and Trademark Office has issued three patents for its proprietary continuous blood glucose monitoring (CBGM) platform, strengthening its intellectual property.

Glucotrack, Inc. announced a $4.0 million private placement of pre-funded and common warrants with a single institutional investor to fund general corporate purposes and working capital.

Glucotrack, Inc. announced the issuance of an investor presentation on December 29, 2025, providing updated information to stakeholders.

Glucotrack reports Q3 2025 financial results, highlighting strengthened balance sheet, progress on its CBGM technology, and an anticipated FDA IDE submission in Spring 2026.

Glucotrack, Inc.'s special meeting of stockholders was permanently adjourned due to a persistent lack of quorum, preventing any business from being conducted.

Glucotrack, Inc. adjourned its special meeting of stockholders due to insufficient attendance, postponing a vote on an 'Issuance Proposal' to November 7, 2025.

Glucotrack, Inc. reconvenes its Special Meeting on November 7, 2025, urging shareholders to vote on a $20 million Equity Purchase Agreement with Sixth Borough Capital Fund LP.

Glucotrack, Inc. announced the appointment of Dr. Usman Latif, a neuromodulation and painful diabetic neuropathy expert, to its clinical advisory team to advance integrated glucose monitoring applications.

Glucotrack, Inc. reminds shareholders to vote on an Equity Purchase Agreement with Sixth Borough Capital Fund at a Special Meeting on October 31, 2025.

Glucotrack, Inc. has issued a $3.6 million principal convertible promissory note for $3 million cash, bearing zero interest and convertible upon a qualified financing.

Glucotrack, Inc. entered into a purchase agreement with Sixth Borough Capital Fund, LP for up to $20 million in common stock, providing flexible capital over 24 months.

Glucotrack reports Q2 2025 financial results, highlights significant clinical progress, and improved capital structure, extending cash runway through 2025.

Glucotrack, Inc. announced the appointment of David S. Hirsh, MD, as Medical Director, Cardiology, to advance its continuous blood glucose monitor through clinical milestones.

Glucotrack, Inc. announced its participation in the 2025 ADCES Annual Meeting to showcase its implantable Continuous Blood Glucose Monitor (CBGM) and present physician perspectives on the technology, as it advances toward a US pilot study.

Glucotrack, Inc. filed an amendment to its 8-K report to include a letter from its former auditor, Grant Thornton, confirming agreement with the company's statements regarding the change in accounting firm.

Glucotrack, Inc. has appointed CBIZ CPAs P.C. as its new independent registered public accounting firm, replacing Grant Thornton, which had previously raised substantial doubt about the company's ability to continue as a going concern and noted material weaknesses in internal controls.